Literature DB >> 4042518

Doxepin plasma concentrations in clinical practice. Could there be a pharmacokinetic explanation for low concentrations?

P R Joyce, J R Sharman.   

Abstract

During therapeutic use of doxepin, we have often observed unexpectedly low doxepin plasma concentrations in patients on moderate dosages, e.g. 100 to 200mg daily. While non-compliance seemed the most likely explanation, we present the data for 6 patients in whom we considered non-compliance unlikely. The data can be explained by hypothesizing that in some patients, there is not a linear dosage-plasma concentration relationship and that on a steady dosage, plasma concentrations are not always maintained. If these phenomena can be more carefully documented they may assume clinical importance; indeed for 2 of the patients studied the falling plasma concentrations on a steady dosage were associated with a recurrence of depression.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4042518     DOI: 10.2165/00003088-198510040-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  9 in total

1.  Nonlinear desipramine pharmacokinetics: a case study.

Authors:  J E Dugas; D S Bishop
Journal:  J Clin Psychopharmacol       Date:  1985-02       Impact factor: 3.153

2.  Apparent nonlinear kinetics of secondary-amine tricyclic antidepressants.

Authors:  A D Spigelman; R C Jansen; R J Bruzek
Journal:  Clin Pharm       Date:  1983 Nov-Dec

3.  Doxepin plasma levels and therapeutic response in depression: preliminary findings.

Authors:  N G Ward; V L Bloom; L Wilson; M Raskind; V A Raisys
Journal:  J Clin Psychopharmacol       Date:  1982-04       Impact factor: 3.153

Review 4.  The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels.

Authors:  J Amsterdam; D Brunswick; J Mendels
Journal:  Am J Psychiatry       Date:  1980-06       Impact factor: 18.112

5.  Clomipramine and doxepin in depressive neurosis. Plasma levels and therapeutic response.

Authors:  M Linnoila; T Seppala; M J Mattila; R Vihko; A Pakarinen; T Skinner
Journal:  Arch Gen Psychiatry       Date:  1980-11

6.  Treatment of depression with tricyclic drugs--pharmacokinetic and pharmacodynamic aspects.

Authors:  M Asberg
Journal:  Pharmakopsychiatr Neuropsychopharmakol       Date:  1976-01

7.  Clinical importance of doxepin antidepressant plasma levels.

Authors:  D O Green
Journal:  J Clin Psychiatry       Date:  1978-05       Impact factor: 4.384

8.  Desipramine plasma concentration and antidepressant response.

Authors:  J C Nelson; P Jatlow; D M Quinlan; M B Bowers
Journal:  Arch Gen Psychiatry       Date:  1982-12

9.  Nortriptyline capacity-limited metabolism: a case report.

Authors:  J L Browne; P J Perry; J W Taylor; B A Sieleni; Z Kronfol
Journal:  J Clin Psychopharmacol       Date:  1984-12       Impact factor: 3.153

  9 in total
  3 in total

1.  Stereoselective pharmacokinetics of doxepin isomers.

Authors:  K K Midha; J W Hubbard; G McKay; E M Hawes; E D Korchinski; T Gurnsey; J K Cooper; R Schwede
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Steady-state kinetics of doxepin and imipramine in Saudi patients with interethnic comparison.

Authors:  A el-Yazigi; K Chaleby
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

3.  Predictions of in vivo plasma concentrations from in vitro release kinetics: application to doxepin parenteral (i.m.) suspensions in lipophilic vehicles in dogs.

Authors:  C Gido; P Langguth; E Mutschler
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.